Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=12390 I recently purchased some of this stock, and have been amazed at the paucity of online talk about it (... maybe a good sign!). A check of Zacks will show that out of 10 broker/analysts covering it, All Ten give it a Strong Buy rating, making it #1 in their rankings out of the 115 stocks in their "Med-Biomed/Gene industry sector -- see ultra.zacks.com To get the ball rolling, I will post some of the data I've collected that's not copyright-protected, & maybe someone will join me in tracking the coming success of this company. Sangstat Medical Corporation offers a broad spectrum of therapeutic and monitoring product candidates to improve the outcome of organ transplants. Of SangStat's 11 products and product candidates, one is a licensed-in, commercially proven drug, 3 are currently available for clinical or research use, and several others are at an advanced stage of development. The company's products include CELSIOR, which preserves organ viability prior to transplantation; sHLA-STAT Class I, which improves the early non-invasive diagnosis of acute rejection episodes; and THYMOGLOBULIN, a commercially-proven drug to treat acute graft rejection episodes and prevent graft loss. https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=1239038013210